{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:36:23Z","timestamp":1790217383186,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T00:00:00Z","timestamp":1693958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T00:00:00Z","timestamp":1693958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s00417-023-06227-6","type":"journal-article","created":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T18:02:17Z","timestamp":1694023337000},"page":"3207-3213","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Visual field after anti-vascular endothelial growth factor therapy and laser treatment for retinopathy of prematurity"],"prefix":"10.1007","volume":"261","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6120-2392","authenticated-orcid":false,"given":"Shumpei","family":"Obata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riko","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maki","family":"Iwasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Kakinoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Sawada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Sawada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitsugu","family":"Saishin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahito","family":"Ohji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,6]]},"reference":[{"key":"6227_CR1","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.earlhumdev.2007.11.009","volume":"84","author":"C Gilbert","year":"2008","unstructured":"Gilbert C (2008) Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control. Early Hum Dev 84:77\u201382. https:\/\/doi.org\/10.1016\/j.earlhumdev.2007.11.009","journal-title":"Early Hum Dev"},{"key":"6227_CR2","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/j.ophtha.2007.07.028","volume":"115","author":"GE Quinn","year":"2008","unstructured":"Quinn GE, Dobson V, Davitt BV, Hardy RJ, Tung B, Pedroza C, Good WV, Early Treatment for Retinopathy of Prematurity Cooperative G (2008) Progression of myopia and high myopia in the early treatment for retinopathy of prematurity study: findings to 3 years of age. Ophthalmology 115:1058-1064 e1051. https:\/\/doi.org\/10.1016\/j.ophtha.2007.07.028","journal-title":"Ophthalmology"},{"key":"6227_CR3","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jaapos.2012.10.025","volume":"17","author":"GE Quinn","year":"2013","unstructured":"Quinn GE, Dobson V, Davitt BV, Wallace DK, Hardy RJ, Tung B, Lai D, Good WV, Early Treatment for Retinopathy of Prematurity Cooperative G (2013) Progression of myopia and high myopia in the early treatment for retinopathy of prematurity study: findings at 4 to 6 years of age. J AAPOS 17:124\u2013128. https:\/\/doi.org\/10.1016\/j.jaapos.2012.10.025","journal-title":"J AAPOS"},{"key":"6227_CR4","doi-asserted-by":"publisher","first-page":"170","DOI":"10.3928\/0191-3913-20070301-10","volume":"44","author":"E McLoone","year":"2007","unstructured":"McLoone E, O\u2019Keefe M, McLoone S, Lanigan B (2007) Effect of diode laser retinal ablative therapy for threshold retinopathy of prematurity on the visual field: results of Goldmann perimetry at a mean age of 11 years. J Pediatr Ophthalmol Strabismus 44:170\u2013173. https:\/\/doi.org\/10.3928\/0191-3913-20070301-10","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"6227_CR5","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","volume":"121","author":"Early Treatment For Retinopathy Of Prematurity Cooperative G","year":"2003","unstructured":"Early Treatment For Retinopathy Of Prematurity Cooperative G (2003) Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 121:1684\u20131694. https:\/\/doi.org\/10.1001\/archopht.121.12.1684","journal-title":"Arch Ophthalmol"},{"key":"6227_CR6","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","volume":"364","author":"HA Mintz-Hittner","year":"2011","unstructured":"Mintz-Hittner HA, Kennedy KA, Chuang AZ, Group B-RC (2011) Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 364:603\u2013615. https:\/\/doi.org\/10.1056\/NEJMoa1007374","journal-title":"N Engl J Med"},{"issue":"1327","key":"6227_CR7","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1001\/jamaophthalmol.2014.2772","volume":"132","author":"MM Geloneck","year":"2014","unstructured":"Geloneck MM, Chuang AZ, Clark WL, Hunt MG, Norman AA, Packwood EA, Tawansy KA, Mintz-Hittner HA, Group B-RC (2014) Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmol 132(1327):1333. https:\/\/doi.org\/10.1001\/jamaophthalmol.2014.2772","journal-title":"JAMA Ophthalmol"},{"key":"6227_CR8","doi-asserted-by":"publisher","first-page":"e0129383","DOI":"10.1371\/journal.pone.0129383","volume":"10","author":"L Pertl","year":"2015","unstructured":"Pertl L, Steinwender G, Mayer C, Hausberger S, Poschl EM, Wackernagel W, Wedrich A, El-Shabrawi Y, Haas A (2015) A systematic review and meta-analysis on the safety of vascular endothelial growth factor (VEGF) inhibitors for the treatment of retinopathy of prematurity. PLoS One 10:e0129383. https:\/\/doi.org\/10.1371\/journal.pone.0129383","journal-title":"PLoS One"},{"key":"6227_CR9","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1136\/bjophthalmol-2013-304109","volume":"98","author":"SG Tahija","year":"2014","unstructured":"Tahija SG, Hersetyati R, Lam GC, Kusaka S, McMenamin PG (2014) Fluorescein angiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zone I and posterior zone II retinopathy of prematurity. Br J Ophthalmol 98:507\u2013512. https:\/\/doi.org\/10.1136\/bjophthalmol-2013-304109","journal-title":"Br J Ophthalmol"},{"key":"6227_CR10","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/j.oret.2018.01.017","volume":"2","author":"R Roohipoor","year":"2018","unstructured":"Roohipoor R, Karkhaneh R, Riazi-Esfahani M, Dastjani Farahani A, Khodabandeh A, Ebrahimi Adib N, Imani M, Khojasteh Jafari H, Riazi-Esfahani H, Hosseinpour J, Zarei M, Ghasemi H, Mirghorbani M, Yaseri M, Davoudi S, Modjtahedi BS (2018) Comparison of intravitreal bevacizumab and laser photocoagulation in the treatment of retinopathy of prematurity. Ophthalmol Retin 2:942\u2013948. https:\/\/doi.org\/10.1016\/j.oret.2018.01.017","journal-title":"Ophthalmol Retin"},{"key":"6227_CR11","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1007\/s00417-019-04292-4","volume":"257","author":"I Perente","year":"2019","unstructured":"Perente I, Eris E, Seymen Z, Cevik SG, Bekmez S (2019) Aggressive posterior retinopathy of prematurity treated with intravitreal bevacizumab: late period fluorescein angiographic findings. Graefes Arch Clin Exp Ophthalmol 257:1141\u20131146. https:\/\/doi.org\/10.1007\/s00417-019-04292-4","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"6227_CR12","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.ophtha.2017.08.005","volume":"125","author":"D Lepore","year":"2018","unstructured":"Lepore D, Quinn GE, Molle F, Orazi L, Baldascino A, Ji MH, Sammartino M, Sbaraglia F, Ricci D, Mercuri E (2018) Follow-up to age 4 years of treatment of type 1 retinopathy of prematurity intravitreal bevacizumab injection versus laser: fluorescein angiographic findings. Ophthalmology 125:218\u2013226. https:\/\/doi.org\/10.1016\/j.ophtha.2017.08.005","journal-title":"Ophthalmology"},{"key":"6227_CR13","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/IAE.0000000000001126","volume":"37","author":"B Lorenz","year":"2017","unstructured":"Lorenz B, Stieger K, Jager M, Mais C, Stieger S, Andrassi-Darida M (2017) Retinal vascular development with 0.312 mg intravitreal bevacizumab to treat severe posterior retinopathy of prematurity: a longitudinal fluorescein angiographic study. Retina 37:97\u2013111. https:\/\/doi.org\/10.1097\/IAE.0000000000001126","journal-title":"Retina"},{"key":"6227_CR14","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1001\/archopht.123.7.991","volume":"123","author":"International Committee for the Classification of Retinopathy of P","year":"2005","unstructured":"International Committee for the Classification of Retinopathy of P (2005) The international classification of retinopathy of prematurity revisited. Arch Ophthalmol 123:991\u2013999. https:\/\/doi.org\/10.1001\/archopht.123.7.991","journal-title":"Arch Ophthalmol"},{"key":"6227_CR15","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3928\/23258160-20170301-10","volume":"48","author":"AR Hajrasouliha","year":"2017","unstructured":"Hajrasouliha AR, Garcia-Gonzales JM, Shapiro MJ, Yoon H, Blair MP (2017) Reactivation of retinopathy of prematurity three years after treatment with bevacizumab. Ophthalmic Surg Lasers Imaging Retina 48:255\u2013259. https:\/\/doi.org\/10.3928\/23258160-20170301-10","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"6227_CR16","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3928\/23258160-20160229-12","volume":"47","author":"LL Snyder","year":"2016","unstructured":"Snyder LL, Garcia-Gonzalez JM, Shapiro MJ, Blair MP (2016) Very late reactivation of retinopathy of prematurity after monotherapy with intravitreal bevacizumab. Ophthalmic Surg Lasers Imaging Retina 47:280\u2013283. https:\/\/doi.org\/10.3928\/23258160-20160229-12","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"6227_CR17","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.jaapos.2013.01.004","volume":"17","author":"S Ittiara","year":"2013","unstructured":"Ittiara S, Blair MP, Shapiro MJ, Lichtenstein SJ (2013) Exudative retinopathy and detachment: a late reactivation of retinopathy of prematurity after intravitreal bevacizumab. J AAPOS 17:323\u2013325. https:\/\/doi.org\/10.1016\/j.jaapos.2013.01.004","journal-title":"J AAPOS"},{"key":"6227_CR18","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ajo.2021.11.015","volume":"238","author":"BS Gundlach","year":"2022","unstructured":"Gundlach BS, Kokhanov A, Altendahl M, Suh SY, Fung S, Demer J, Pineles S, Khitri M, Chu A, Tsui I (2022) Real-world visual outcomes of laser and anti-VEGF treatments for retinopathy of prematurity. Am J Ophthalmol 238:86\u201396. https:\/\/doi.org\/10.1016\/j.ajo.2021.11.015","journal-title":"Am J Ophthalmol"},{"key":"6227_CR19","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ajo.2018.05.002","volume":"192","author":"YS Lee","year":"2018","unstructured":"Lee YS, See LC, Chang SH, Wang NK, Hwang YS, Lai CC, Chen KJ, Wu WC (2018) Macular structures, optical components, and visual acuity in preschool children after intravitreal bevacizumab or laser treatment. Am J Ophthalmol 192:20\u201330. https:\/\/doi.org\/10.1016\/j.ajo.2018.05.002","journal-title":"Am J Ophthalmol"},{"key":"6227_CR20","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1136\/bjophthalmol-2019-314610","volume":"104","author":"YC Chen","year":"2020","unstructured":"Chen YC, Chen SN (2020) Foveal microvasculature, refractive errors, optical biometry and their correlations in school-aged children with retinopathy of prematurity after intravitreal antivascular endothelial growth factors or laser photocoagulation. Br J Ophthalmol 104:691\u2013696. https:\/\/doi.org\/10.1136\/bjophthalmol-2019-314610","journal-title":"Br J Ophthalmol"},{"key":"6227_CR21","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1136\/bjophthalmol-2019-315520","volume":"104","author":"J Zhao","year":"2020","unstructured":"Zhao J, Wu Z, Lam W, Yang M, Chen L, Zheng L, Zhang F, Zeng J, Wang J, Zhang G (2020) Comparison of OCT angiography in children with a history of intravitreal injection of ranibizumab versus laser photocoagulation for retinopathy of prematurity. Br J Ophthalmol 104:1556\u20131560. https:\/\/doi.org\/10.1136\/bjophthalmol-2019-315520","journal-title":"Br J Ophthalmol"},{"key":"6227_CR22","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s00417-020-04946-8","volume":"259","author":"T Inoue","year":"2021","unstructured":"Inoue T, Asaoka R, Hashimoto Y, Kitamoto K, Kitano M, Fujita A, Azuma K, Yamamoto K, Nagahara M, Kadonosono K, Obata R (2021) Does the number of laser applications for ROP treatment influence the degree of myopia? Graefes Arch Clin Exp Ophthalmol 259:317\u2013322. https:\/\/doi.org\/10.1007\/s00417-020-04946-8","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"6227_CR23","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1007\/s10384-022-00921-4","volume":"66","author":"S Matsumura","year":"2022","unstructured":"Matsumura S, Matsumoto T, Katayama Y, Tomita M, Morikawa H, Itokawa T, Kawakami M, Hori Y (2022) Risk factors for early-onset high myopia after treatment for retinopathy of prematurity. Jpn J Ophthalmol 66:386\u2013393. https:\/\/doi.org\/10.1007\/s10384-022-00921-4","journal-title":"Jpn J Ophthalmol"},{"key":"6227_CR24","doi-asserted-by":"publisher","first-page":"314","DOI":"10.3928\/0191-3913-19911101-07","volume":"28","author":"GE Quinn","year":"1991","unstructured":"Quinn GE, Fea AM, Minguini N (1991) Visual fields in 4- to 10-year-old children using Goldmann and double-arc perimeters. J Pediatr Ophthalmol Strabismus 28:314\u2013319. https:\/\/doi.org\/10.3928\/0191-3913-19911101-07","journal-title":"J Pediatr Ophthalmol Strabismus"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-023-06227-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-023-06227-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-023-06227-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T09:06:53Z","timestamp":1697706413000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-023-06227-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,6]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["6227"],"URL":"https:\/\/doi.org\/10.1007\/s00417-023-06227-6","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,6]]},"assertion":[{"value":"13 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. The study was approved by the Institutional Review Board\/Ethics Committee of Shiga University of Medical Science (Otsu, Japan).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"For this study, an opt-out consent process was used at Shiga University of Medical Science Hospital after approval by the Institutional Review Board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}